Moderna Cuts $2.2B Costs in 2025, MNEXT Spike Captures 24% U.S. Market
Moderna reduced operating expenses by $2.2bn in 2025, beating cost-cut targets by over $1bn. MNEXT Spike captured 24% of U.S. retail COVID vaccine market while FDA refused to file the mRNA-1010 flu shot, prompting a strategic pivot to sovereign partnerships and advancing three late-stage oncology trials.
1. Cost Reduction Outperformance
Moderna cut operating expenses by $2.2 billion in 2025, exceeding its initial target by $1 billion, underscoring management’s focus on margin expansion and operational efficiency.
2. MNEXT Spike Market Share
The U.S. launch of MNEXT Spike drove retail COVID vaccine revenue, capturing 24% of the total market despite declining demand, bolstering Moderna’s commercial growth outside pandemic peak periods.
3. Flu Vaccine Regulatory Setback
Moderna received a Refusal to File letter from the FDA for its mRNA-1010 flu vaccine, citing unpredictable regulatory requirements, which delays the program and may require additional data or submissions.
4. Strategic Pivot and Oncology Progress
The company plans to establish long-term partnerships with the U.K., Canada and Australia to secure annualized revenue streams from 2026 and has completed enrollment in three late-stage oncology studies targeting melanoma, renal cell and bladder cancers.